These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23819497)

  • 1. Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy.
    Wu Y; Yan S; Lv Z; Chen L; Geng J; He J; Yu Q; Yin J; Ren G; Li D
    Technol Cancer Res Treat; 2014 Apr; 13(2):169-75. PubMed ID: 23819497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy.
    Wu Y; He J; An Y; Wang X; Liu Y; Yan S; Ye X; Qi J; Zhu S; Yu Q; Yin J; Li D; Wang W
    J Pharmacol Sci; 2016 Sep; 132(1):24-30. PubMed ID: 27174862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy.
    Wu Y; He J; Geng J; An Y; Ye X; Yan S; Yu Q; Yin J; Zhang Z; Li D
    Eur J Pharmacol; 2017 May; 802():85-92. PubMed ID: 28246027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.
    Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D
    Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.
    An Y; Liu T; He J; Wu H; Chen R; Liu Y; Wu Y; Bai Y; Guo X; Zheng Q; Liu C; Yin J; Li D; Ren G
    J Biomed Sci; 2016 Jul; 23(1):55. PubMed ID: 27465066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model.
    He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y
    J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
    Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
    Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
    He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J
    Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
    Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
    Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
    Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
    J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting.
    Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G
    Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
    Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
    Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.
    Altomonte J; Marozin S; Schmid RM; Ebert O
    Mol Ther; 2010 Feb; 18(2):275-84. PubMed ID: 19809404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.
    Bian H; Fournier P; Moormann R; Peeters B; Schirrmacher V
    Int J Oncol; 2005 Feb; 26(2):431-9. PubMed ID: 15645128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice.
    Dai M; Liu J; Chen DE; Rao Y; Tang ZJ; Ho WZ; Dong CY
    Cancer Gene Ther; 2012 Feb; 19(2):77-83. PubMed ID: 21959967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
    Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
    Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.